NO20081727L - Behandling av autoimmune sykdommer - Google Patents

Behandling av autoimmune sykdommer

Info

Publication number
NO20081727L
NO20081727L NO20081727A NO20081727A NO20081727L NO 20081727 L NO20081727 L NO 20081727L NO 20081727 A NO20081727 A NO 20081727A NO 20081727 A NO20081727 A NO 20081727A NO 20081727 L NO20081727 L NO 20081727L
Authority
NO
Norway
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
methods
Prior art date
Application number
NO20081727A
Other languages
English (en)
Norwegian (no)
Inventor
Rainer Albert
Nigel Graham Cooke
Sven Weiler
Barbara Nuesslein-Hildesheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20081727L publication Critical patent/NO20081727L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20081727A 2005-09-09 2008-04-07 Behandling av autoimmune sykdommer NO20081727L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09
PCT/EP2006/066150 WO2007028821A2 (fr) 2005-09-09 2006-09-07 Traitement de maladies auto-immunes

Publications (1)

Publication Number Publication Date
NO20081727L true NO20081727L (no) 2008-06-06

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081727A NO20081727L (no) 2005-09-09 2008-04-07 Behandling av autoimmune sykdommer

Country Status (28)

Country Link
US (1) US20080200438A1 (fr)
EP (2) EP1926483B1 (fr)
JP (4) JP5244598B2 (fr)
KR (3) KR101476591B1 (fr)
CN (1) CN101257899B (fr)
AT (1) ATE489948T1 (fr)
AU (2) AU2006289100B2 (fr)
BR (1) BRPI0615906A2 (fr)
CA (2) CA2820510A1 (fr)
CY (1) CY1111285T1 (fr)
DE (1) DE602006018629D1 (fr)
DK (2) DK2295049T3 (fr)
ES (2) ES2529724T3 (fr)
IL (2) IL189665A (fr)
JO (1) JO2655B1 (fr)
MA (1) MA29787B1 (fr)
MX (1) MX2008003170A (fr)
NO (1) NO20081727L (fr)
NZ (2) NZ588372A (fr)
PL (2) PL1926483T3 (fr)
PT (2) PT2295049E (fr)
RU (2) RU2424795C2 (fr)
SG (1) SG165364A1 (fr)
SI (2) SI1926483T1 (fr)
TN (1) TNSN08103A1 (fr)
TW (2) TWI372620B (fr)
WO (1) WO2007028821A2 (fr)
ZA (1) ZA200801694B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781617B2 (en) 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP1806338B1 (fr) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Procédé de synthèse de l hydrochlorure de 2-amino-2-[2-[4-(3-benzyloxy-phénylthio)-2-chlorophényl[éthyl]-1,3-propanediol et des hydrates de ce composé, et intermédiaires de synthèse de celles-ci
PL1932522T3 (pl) * 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2659598A1 (fr) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Derive d'ester de l'acide aminophosphorique et modulateur durecepteur s1p contenant ledit derive en tant que principe actif
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
WO2008099781A1 (fr) * 2007-02-13 2008-08-21 Kyorin Pharmaceutical Co., Ltd. Agent thérapeutique ou prophylactique pour une maladie démyélinisante comprenant un dérivé d'amino alcool comme ingrédient actif
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
CA2724592A1 (fr) * 2008-05-20 2009-11-26 Kyorin Pharmaceutical Co., Ltd. Agent d~induction/d~entretien de remission
WO2010020609A1 (fr) * 2008-08-18 2010-02-25 Novartis Ag Dérivés d’amino-alcools destinés au traitement de neuropathies périphériques démyélinisantes
BR112012028248A2 (pt) * 2010-05-06 2016-08-02 Novartis Ag derivados de sulfeto de diarila, seu uso, e kit
KR20130066630A (ko) * 2010-05-06 2013-06-20 노파르티스 아게 자가면역 질환의 치료

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CA2461212C (fr) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, sels correspondant et agents immunosuppresseur utilisant ces derives
JP4571497B2 (ja) * 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
EP1575576A2 (fr) * 2002-09-24 2005-09-21 Novartis AG Composes organiques
KR100995486B1 (ko) * 2002-09-28 2010-11-22 맥네일-피피씨, 인코포레이티드 개구가 있는 쉘을 포함하는 속방성 투여형
BRPI0407658A (pt) * 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
PE20130200A1 (es) * 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
WO2005014525A2 (fr) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Compose bi-aryle presentant une activite immunosuppressive
ATE449069T1 (de) * 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR101476451B1 (ko) 2014-12-24
IL189665A (en) 2014-07-31
JP2017019854A (ja) 2017-01-26
JO2655B1 (en) 2012-06-17
KR20140019033A (ko) 2014-02-13
MA29787B1 (fr) 2008-09-01
WO2007028821A2 (fr) 2007-03-15
JP6077265B2 (ja) 2017-02-08
TW201034659A (en) 2010-10-01
IL189665A0 (en) 2008-06-05
CY1111285T1 (el) 2015-08-05
JP2009507810A (ja) 2009-02-26
CN101257899A (zh) 2008-09-03
NZ566137A (en) 2011-05-27
BRPI0615906A2 (pt) 2011-05-31
JP5244598B2 (ja) 2013-07-24
TW200803829A (en) 2008-01-16
JP2013010802A (ja) 2013-01-17
SI1926483T1 (sl) 2011-04-29
KR20080046231A (ko) 2008-05-26
DK1926483T3 (da) 2011-03-14
EP2295049B1 (fr) 2014-11-26
CA2620554C (fr) 2013-12-17
DE602006018629D1 (de) 2011-01-13
IL233328A0 (en) 2014-08-31
SG165364A1 (en) 2010-10-28
MX2008003170A (es) 2008-03-18
CN101257899B (zh) 2012-10-03
TWI372620B (en) 2012-09-21
TNSN08103A1 (en) 2009-07-14
RU2008113187A (ru) 2009-10-20
ATE489948T1 (de) 2010-12-15
EP2295049A1 (fr) 2011-03-16
AU2010224355B2 (en) 2012-03-29
ZA200801694B (en) 2009-09-30
DK2295049T3 (en) 2015-02-23
NZ588372A (en) 2012-03-30
AU2006289100B2 (en) 2010-07-22
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
SI2295049T1 (sl) 2015-03-31
ES2357426T3 (es) 2011-04-26
AU2006289100A1 (en) 2007-03-15
RU2424795C2 (ru) 2011-07-27
KR20140117704A (ko) 2014-10-07
EP1926483B1 (fr) 2010-12-01
ES2529724T3 (es) 2015-02-25
PL1926483T3 (pl) 2011-05-31
PT2295049E (pt) 2015-03-02
PL2295049T3 (pl) 2015-04-30
TWI376223B (en) 2012-11-11
EP1926483A2 (fr) 2008-06-04
CA2820510A1 (fr) 2007-03-15
RU2011111117A (ru) 2012-09-27
JP2015025002A (ja) 2015-02-05
HK1149906A1 (en) 2011-10-21
AU2010224355A1 (en) 2010-10-14
PT1926483E (pt) 2011-03-03
CA2620554A1 (fr) 2007-03-15
WO2007028821A3 (fr) 2007-05-03
RU2493840C2 (ru) 2013-09-27

Similar Documents

Publication Publication Date Title
NO20081727L (no) Behandling av autoimmune sykdommer
NO20054407L (no) Cannabinoid reseptor ligander og deres anvendelser
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
NO20072092L (no) Sulfonamidforbindelser
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
NO20076401L (no) Diarylhydantoinforbindelser
MX2009011210A (es) Inhibidores de mcl1 de indol 7-no sustituido.
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
UA85559C2 (en) Aminobenzophenone compounds
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
NO20076412L (no) Heterosykliske inhibitorer av mek og fremgangsmater for anvendelse derav
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
NO20080318L (no) Anvendelse av enkelt dose av CD-20-spesifikke bindingsmolekyler
NO20075706L (no) Pyrrolopyridinbaserte inhibitorer av dipeptidylpeptidase IV og metoder
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
WO2006034391A3 (fr) Inhibiteurs d'indole de 15-lipoxygenase
WO2025188662A8 (fr) Modulateurs d'akt1
TW200628453A (en) Triazole substituted aminobenzophenone compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application